Intracerebral Hemorrhage

Continuum (Minneap Minn). 2021 Oct 1;27(5):1246-1277. doi: 10.1212/CON.0000000000001018.

Abstract

Purpose of review: Nontraumatic intracerebral hemorrhage (ICH) is the second most common type of stroke. This article summarizes the basic pathophysiology, classification, and management of ICH and discusses the available evidence on therapy for hematoma, hematoma expansion, and perihematomal edema.

Recent findings: Current available data on potential therapeutic options for ICH are promising, although none of the trials have shown improvement in mortality rate. The literature available on reversal of anticoagulation and antiplatelet agents after an ICH and resumption of these medications is also increasing.

Summary: ICH continues to have high morbidity and mortality. Advances in therapeutic options to target secondary brain injury from the hematoma, hematoma expansion, and perihematomal edema are increasing. Data on reversal therapy for anticoagulant-associated or antiplatelet-associated ICH and resumption of these medications are evolving.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Anticoagulation Reversal
  • Brain Edema* / drug therapy
  • Brain Edema* / etiology
  • Cerebral Hemorrhage / drug therapy
  • Hematoma / therapy
  • Humans
  • Stroke* / complications
  • Stroke* / diagnosis
  • Stroke* / drug therapy

Substances

  • Anticoagulants